IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-17645-z.html
   My bibliography  Save this article

Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer

Author

Listed:
  • Jody Vykoukal

    (The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center)

  • Johannes F. Fahrmann

    (The University of Texas MD Anderson Cancer Center)

  • Justin R. Gregg

    (The University of Texas MD Anderson Cancer Center)

  • Zhe Tang

    (The University of Texas MD Anderson Cancer Center)

  • Spyridon Basourakos

    (The University of Texas MD Anderson Cancer Center)

  • Ehsan Irajizad

    (The University of Texas MD Anderson Cancer Center)

  • Sanghee Park

    (The University of Texas MD Anderson Cancer Center)

  • Guang Yang

    (The University of Texas MD Anderson Cancer Center)

  • Chad J. Creighton

    (The University of Texas MD Anderson Cancer Center
    Baylor College of Medicine, One Baylor Plaza)

  • Alia Fleury

    (The University of Texas MD Anderson Cancer Center)

  • Jeffrey Mayo

    (The University of Texas MD Anderson Cancer Center)

  • Adriana Paulucci-Holthauzen

    (The University of Texas MD Anderson Cancer Center)

  • Jennifer B. Dennison

    (The University of Texas MD Anderson Cancer Center)

  • Eunice Murage

    (The University of Texas MD Anderson Cancer Center)

  • Christine B. Peterson

    (The University of Texas MD Anderson Cancer Center)

  • John W. Davis

    (The University of Texas MD Anderson Cancer Center)

  • Jeri Kim

    (The University of Texas MD Anderson Cancer Center)

  • Samir Hanash

    (The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center)

  • Timothy C. Thompson

    (The University of Texas MD Anderson Cancer Center)

Abstract

Plasma and tumor caveolin-1 (Cav-1) are linked with disease progression in prostate cancer. Here we report that metabolomic profiling of longitudinal plasmas from a prospective cohort of 491 active surveillance (AS) participants indicates prominent elevations in plasma sphingolipids in AS progressors that, together with plasma Cav-1, yield a prognostic signature for disease progression. Mechanistic studies of the underlying tumor supportive onco-metabolism reveal coordinated activities through which Cav-1 enables rewiring of cancer cell lipid metabolism towards a program of 1) exogenous sphingolipid scavenging independent of cholesterol, 2) increased cancer cell catabolism of sphingomyelins to ceramide derivatives and 3) altered ceramide metabolism that results in increased glycosphingolipid synthesis and efflux of Cav-1-sphingolipid particles containing mitochondrial proteins and lipids. We also demonstrate, using a prostate cancer syngeneic RM-9 mouse model and established cell lines, that this Cav-1-sphingolipid program evidences a metabolic vulnerability that is targetable to induce lethal mitophagy as an anti-tumor therapy.

Suggested Citation

  • Jody Vykoukal & Johannes F. Fahrmann & Justin R. Gregg & Zhe Tang & Spyridon Basourakos & Ehsan Irajizad & Sanghee Park & Guang Yang & Chad J. Creighton & Alia Fleury & Jeffrey Mayo & Adriana Paulucci, 2020. "Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer," Nature Communications, Nature, vol. 11(1), pages 1-16, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17645-z
    DOI: 10.1038/s41467-020-17645-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-17645-z
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-17645-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Hanyu Rao & Changwei Liu & Aiting Wang & Chunxiao Ma & Yue Xu & Tianbao Ye & Wenqiong Su & Peijun Zhou & Wei-Qiang Gao & Li Li & Xianting Ding, 2023. "SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer," Nature Communications, Nature, vol. 14(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17645-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.